Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling

BACKGROUND: Phosphatase and tensin homolog (PTEN) loss is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer. However, the clinical value of PTEN as a biomarker in these patients is controversial. We sought to determine whether the benefit of traditional biomar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajjadi, Elham, Venetis, Konstantinos, Piciotti, Roberto, Gambini, Donatella, Blundo, Concetta, Runza, Letterio, Ferrero, Stefano, Guerini-Rocco, Elena, Fusco, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555186/
https://www.ncbi.nlm.nih.gov/pubmed/34706703
http://dx.doi.org/10.1186/s12885-021-08889-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555186/
https://www.ncbi.nlm.nih.gov/pubmed/34706703
http://dx.doi.org/10.1186/s12885-021-08889-z

Ejemplares similares